OLD National Bancorp IN boosted its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 38.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,714 shares of the medical research company’s stock after acquiring an additional 6,004 shares during the quarter. OLD National Bancorp IN’s holdings in NeoGenomics were worth $242,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Mesirow Financial Investment Management Inc. bought a new stake in NeoGenomics in the second quarter valued at about $651,000. The Manufacturers Life Insurance Company grew its stake in NeoGenomics by 7.1% during the second quarter. The Manufacturers Life Insurance Company now owns 46,245 shares of the medical research company’s stock worth $414,000 after buying an additional 3,058 shares during the last quarter. State Street Corp grew its stake in NeoGenomics by 8.1% during the second quarter. State Street Corp now owns 999,012 shares of the medical research company’s stock worth $8,953,000 after buying an additional 74,751 shares during the last quarter. Janus Henderson Group PLC bought a new stake in NeoGenomics during the second quarter worth about $20,651,000. Finally, Goldman Sachs Group Inc. grew its stake in NeoGenomics by 79.2% during the second quarter. Goldman Sachs Group Inc. now owns 30,678 shares of the medical research company’s stock worth $275,000 after buying an additional 13,561 shares during the last quarter. 79.74% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.com-unik.info/2017/11/03/old-national-bancorp-in-has-242000-position-in-neogenomics-inc-neo.html.
NeoGenomics (NASDAQ:NEO) last issued its earnings results on Wednesday, October 25th. The medical research company reported $0.01 EPS for the quarter, meeting the consensus estimate of $0.01. The company had revenue of $63.05 million during the quarter, compared to analysts’ expectations of $63.11 million. NeoGenomics had a negative net margin of 4.78% and a positive return on equity of 3.98%. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.04 EPS.
NEO has been the topic of several research analyst reports. Janney Montgomery Scott reaffirmed a “buy” rating on shares of NeoGenomics in a research note on Thursday, October 26th. Zacks Investment Research cut shares of NeoGenomics from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th. BidaskClub cut shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 13th. Gabelli assumed coverage on shares of NeoGenomics in a research note on Thursday, August 24th. They set a “buy” rating and a $9.00 price target on the stock. Finally, BTIG Research reissued a “hold” rating on shares of NeoGenomics in a research note on Sunday, October 29th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $10.33.
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
What are top analysts saying about NeoGenomics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NeoGenomics Inc. and related companies.